Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 264

    1.

    The effect of radiation on semen quality and fertility in men treated with brachytherapy for early stage prostate cancer.

    Singh DK, Hersey K, Perlis N, Crook J, Jarvi K, Fleshner N.

    J Urol. 2012 Mar;187(3):987-9. Epub 2012 Jan 20.

    PMID:
    22264453
    [PubMed - indexed for MEDLINE]
    2.

    Impact of distance to a urologist on early diagnosis of prostate cancer among black and white patients.

    Holmes JA, Carpenter WR, Wu Y, Hendrix LH, Peacock S, Massing M, Schenck AP, Meyer AM, Diao K, Wheeler SB, Godley PA, Stitzenberg KB, Chen RC.

    J Urol. 2012 Mar;187(3):883-8. Epub 2012 Jan 15.

    PMID:
    22248516
    [PubMed - indexed for MEDLINE]
    3.

    Focal therapy will become standard treatment for localized prostate cancer: con.

    Nelson JB.

    J Urol. 2012 Mar;187(3):791-2. Epub 2012 Jan 15. No abstract available.

    PMID:
    22248515
    [PubMed - indexed for MEDLINE]
    4.

    Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion.

    Salagierski M, Schalken JA.

    J Urol. 2012 Mar;187(3):795-801. Epub 2012 Jan 15. Review.

    PMID:
    22245323
    [PubMed - indexed for MEDLINE]
    5.

    Racial differences in bone mineral density and fractures in men receiving androgen deprivation therapy for prostate cancer.

    Morgans AK, Hancock ML, Barnette KG, Steiner MS, Morton RA, Smith MR.

    J Urol. 2012 Mar;187(3):889-93. Epub 2012 Jan 15.

    PMID:
    22245322
    [PubMed - indexed for MEDLINE]
    6.

    Re: Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.

    Walsh PC.

    J Urol. 2012 Jan;187(1):144-5. Epub 2011 Nov 25. No abstract available.

    PMID:
    22153428
    [PubMed - in process]
    7.

    Re: A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment.

    Walsh PC.

    J Urol. 2012 Jan;187(1):143. Epub 2011 Nov 25. No abstract available.

    PMID:
    22153427
    [PubMed - in process]
    8.

    Re: Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3,009,258 men.

    Walsh PC.

    J Urol. 2012 Jan;187(1):142. Epub 2011 Nov 25. No abstract available.

    PMID:
    22153426
    [PubMed - in process]
    9.

    Re: Smoking and prostate cancer survival and recurrence.

    Walsh PC.

    J Urol. 2012 Jan;187(1):141-2. Epub 2011 Nov 25. No abstract available.

    PMID:
    22153425
    [PubMed - in process]
    10.

    Antioxidant therapy alleviates oxidative stress by androgen deprivation and prevents conversion from androgen dependent to castration resistant prostate cancer.

    Shiota M, Song Y, Takeuchi A, Yokomizo A, Kashiwagi E, Kuroiwa K, Tatsugami K, Uchiumi T, Oda Y, Naito S.

    J Urol. 2012 Feb;187(2):707-14. Epub 2011 Dec 16.

    PMID:
    22177207
    [PubMed - indexed for MEDLINE]
    11.

    Re: Differential transformation capacity of Src family kinases during the initiation of prostate cancer.

    Atala A.

    J Urol. 2011 Dec;186(6):2493. Epub 2011 Oct 26. No abstract available.

    PMID:
    22078625
    [PubMed]
    12.

    Re: Role of autonomous androgen receptor signaling in prostate cancer initiation is dichotomous and depends on the oncogenic signal.

    Atala A.

    J Urol. 2011 Dec;186(6):2493-4. Epub 2011 Oct 26. No abstract available.

    PMID:
    22078624
    [PubMed]
    13.

    Re: Mortality trends for benign prostatic hyperplasia and prostate cancer in English populations 1979-2006.

    Kaplan SA.

    J Urol. 2011 Dec;186(6):2332. Epub 2011 Oct 26. No abstract available.

    PMID:
    22078611
    [PubMed - indexed for MEDLINE]
    14.

    Re: Penile implant utilization following treatment for prostate cancer: analysis of the SEER-Medicare database.

    Morey AF.

    J Urol. 2011 Dec;186(6):2299-300. Epub 2011 Oct 22. No abstract available.

    PMID:
    22078601
    [PubMed]
    15.

    Re: A clinically relevant approach to imaging prostate cancer: review.

    Siegel C.

    J Urol. 2011 Dec;186(6):2255. Epub 2011 Oct 22. No abstract available.

    PMID:
    22078587
    [PubMed]
    17.

    Re: Abiraterone and increased survival in metastatic prostate cancer.

    Walsh PC.

    J Urol. 2011 Dec;186(6):2253-4. Epub 2011 Oct 22. No abstract available.

    PMID:
    22078584
    [PubMed]
    18.

    Re: Small prostate size and high grade disease--biology or artifact?: J. J. Liu, J. D. Brooks, M. Ferrari, R. Nolley and J. C. Presti, Jr. J Urol 2011; 185: 2108-2111.

    Calışkan S.

    J Urol. 2011 Dec;186(6):2504; author reply 2504-5. Epub 2011 Oct 22. No abstract available.

    PMID:
    22019038
    [PubMed - indexed for MEDLINE]
    19.

    Editorial comment.

    Muller RL, Moreira DM.

    J Urol. 2011 Dec;186(6):2238; discussion 2238. Epub 2011 Oct 22. No abstract available.

    PMID:
    22019029
    [PubMed - indexed for MEDLINE]
    20.

    A novel stereotactic prostate biopsy system integrating pre-interventional magnetic resonance imaging and live ultrasound fusion.

    Hadaschik BA, Kuru TH, Tulea C, Rieker P, Popeneciu IV, Simpfendörfer T, Huber J, Zogal P, Teber D, Pahernik S, Roethke M, Zamecnik P, Roth W, Sakas G, Schlemmer HP, Hohenfellner M.

    J Urol. 2011 Dec;186(6):2214-20. Epub 2011 Oct 19.

    PMID:
    22014798
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk